Assessment of hematological toxicity and risk stratification in children aged 1-12 years with acute lymphoblastic leukemia receiving ALL COG protocol: a prospective observational study from a tertiary care center in central India
DOI:
https://doi.org/10.18203/2349-3291.ijcp20253780Keywords:
Acute lymphoblastic leukemia, Chemotherapy, Haematological toxicity, MRD, Pediatric oncologyAbstract
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and while standardized chemotherapy protocols have improved survival, treatment-related haematological toxicities remain a significant challenge in low- and middle-income countries.
Methods: A prospective observational study was conducted on 42 children aged 1–12 years with newly diagnosed ALL at a tertiary care center in Central India between 2023 and 2025. Clinical, hematological, immunophenotypic, cytogenetic and Minimal Residual Disease (MRD) data were collected and analyzed.
Results: The cohort comprised 52.4% males, with mean age 7 years. B-cell ALL accounted for 83.3% of cases. Risk stratification revealed 64.3% intermediate-risk, 21.4% high-risk and 14.3% standard-risk. Pallor (85.7%) and fever (73.8%) were the most common presentations. Haematological toxicities particularly neutropenia, anemia and thrombocytopenia were more frequent in higher-risk groups and necessitated frequent transfusions. MRD negativity post-induction was achieved in 78.6% of patients and strongly correlated with remission (p<0.001).
Conclusions: Haematological toxicities significantly impact survival in pediatric ALL, particularly in high-risk groups. MRD remains a powerful prognostic marker. Strengthening supportive care, infection prevention and strategies to reduce treatment abandonment are essential to improve outcomes in resource-limited settings.
Metrics
References
Mohammadian-Hafshejani A, Farber IM, Kheiri S. Global incidence and mortality of childhood leukemia and its relationship with the Human Development Index. PLoS One. 2024;2;19(7):304354. DOI: https://doi.org/10.1371/journal.pone.0304354
Shweta J, Dinesh K. Acute Lymphoblastic Leukemia in Indian Children at a Tertiary Care Center: A Multiparametric Study with Prognostic Implications. National J Clin Ana. 2021;10(4):214-9. DOI: https://doi.org/10.4103/NJCA.NJCA_49_21
Asthana S, Labani S, Mehrana S, Bakhshi S. Incidence of childhood leukemia and lymphoma in India. Pediatric Hematol Oncol J. 2018;3(4):115-20. DOI: https://doi.org/10.1016/j.phoj.2017.12.004
Liu W, Fang J, Zhu M. Global, regional and national burden of childhood leukemia from 1990 to 2021. BMC Pediatr. 2025;25:571. DOI: https://doi.org/10.1186/s12887-025-05847-7
Vikramjit K. Acute childhood leukemia in India: Where are we going, where have we been?. South Asian J Cancer. 2016;5:154. DOI: https://doi.org/10.4103/2278-330X.187590
Ali AM, Adam H, Hailu D, Coenen MJH, Howe R, Abula T. Incidence and determinants of hematotoxicity in acute lymphoblastic leukemia children who received 6-mercaptopurine based maintenance therapy in Addis Ababa, Ethiopia. PLoS ONE. 2023;18(6):286544. DOI: https://doi.org/10.1371/journal.pone.0286544
Hijiya N, van der Sluis IM, Carroll WL. Advances in the treatment of childhood acute lymphoblastic leukemia: challenges and opportunities. Blood Rev. 2015;29(4):223–30.
Pui CH, Campana D, Pei D. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2015;373:1541–52.
Hough R. Crisis management in the treatment of childhood acute lymphoblastic leukaemia. Br J Haematol. 2017;177(5):697–709.
Cheng Y, Wang L, Zhang Y. Carboplatin-induced hematotoxicity among patients with cancer: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2016;77(4):679–89.
Birch JM, Marsden HB. Hematologic toxicity in children with cancer. Br J Cancer. 1994;70(2):315–9.
Cooper SL. Treatment of pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014;2(1):526–34.
Chawla N, Sinha R, Sood A. Long-term effects of pediatric acute lymphoblastic leukemia treatment: cardiovascular and metabolic outcomes. Front Oncol. 2021;11:710163. DOI: https://doi.org/10.3389/fonc.2021.710163
Özdemir ZC, Kar YD, Turhan AB, Bör Ö. Assessment of hematological toxicity in children with acute lymphoblastic leukemia, receiving treatment with ALL IC-BFM 2009 protocol. Open Access Libr J. 2017;4:3807. DOI: https://doi.org/10.4236/oalib.1103807
Selvan M, Ramamoorthy S. Treatment-related toxicity profile in children with acute lymphoblastic leukemia: a prospective cohort study. Indian J Med Paediatr Oncol. 2025;46(3):350–6.
Gaynon PS. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Cancer. 1997;80(9):1717–26. DOI: https://doi.org/10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B
Hassan TH. Predictive value of miRNA-181a in pediatric acute lymphoblastic leukemia. J Cancer Ther. 2020;11(11):673–82. DOI: https://doi.org/10.4236/jct.2020.1111057
Schrappe M. Long-term results of the ALL-BFM 2000 study for children and adolescents with acute lymphoblastic leukemia: minimal residual disease–directed therapy and age/white blood cell–based risk stratification. Leukemia. 2010;24:365–77.
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52. DOI: https://doi.org/10.1056/NEJMra1400972
Faruqui N, Bernays S, Martiniuk A. Access to care for childhood cancers in India: perspectives of health care providers and the implications for universal health coverage. BMC Public Health. 2020;20:1641. DOI: https://doi.org/10.1186/s12889-020-09758-3
Gupta S. Delayed diagnosis of childhood cancers in India: impact on treatment outcomes. Indian J Pediatr. 2017;84(7):511–6. DOI: https://doi.org/10.1007/s12098-017-2380-7
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–55. DOI: https://doi.org/10.1016/S0140-6736(12)62187-4
Locatelli F. Supportive care in pediatric acute lymphoblastic leukemia: managing cytopenias and transfusions. Pediatr Blood Cancer. 2012;58:487–92.
Downloads
Published
How to Cite
Issue
Section
